Evidence map›Paper›PMID 29340518›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2018

Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis.

X Zhang, Y Song, N Song, L Zhang, Y Wang, D Li, Z Wang, X Qu, Y Liu

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

X ZhangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Y SongDepartment of Surgical Oncology, The First Hospital of China Medical University, Shenyang, China.
N SongDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
L ZhangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Y WangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
D LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Z WangDepartment of Surgical Oncology, The First Hospital of China Medical University, Shenyang, China.
X QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Y LiuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The receptor activator of nuclear factor κB ligand (RANKL)/RANK pathway plays an important role in the prognosis of several solid tumor types, but its role in gastric cancer prognosis has been poorly characterized. A total of 116 gastric cancer patients who underwent surgical resection were enrolled in this study. Expressions of RANKL and RANK in gastric cancer tissues were detected using immunohistochemical staining. Thirty-eight patients (33%) showed a high level of RANKL expression and 61 patients (53%) showed a high level of RANK expression. There was a positive correlation between expressions of RANKL and RANK (P=0.014, r=0.221). A high level of RANKL expression indicated shorter overall survival (OS) (P=0.008), and was associated with a higher pathological tumor/lymph node/metastasis (pTNM) stage (P=0.035), while no significant correlation was detected between RANK expression and clinicopathological parameters. RANKL also predicted poor prognosis in patients with high RANK expression (P=0.008) and Bormann's type III/IV (P=0.002). Furthermore, RANKL expression correlated with pTNM stage according to high RANK expression (P=0.009), while no significance was found in patients with low RANK expression (P=1.000). Together, our results revealed that high expression of RANKL could predict worse outcomes in gastric cancer especially combined with RANK detection, and thereby this pathway could be a useful prognostic indicator of gastric cancer.

Indexed as

AdenocarcinomaChinaFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedNeoplasm GradingNeoplasm ProteinsNeoplasm StagingPrognosisRANK LigandRetrospective StudiesStatistics, NonparametricStomach NeoplasmsNeoplasm ProteinsRANK LigandTNFSF11 protein, human

Identifiers

PMID29340518
PMCPMC5769752
OpenAlexW2782778013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.